Phillips Wealth Planners LLC grew its position in Novo Nordisk A/S (NYSE:NVO – Free Report) by 8.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,750 shares of the company’s stock after buying an additional 203 shares during the quarter. Phillips Wealth Planners LLC’s holdings in Novo Nordisk A/S were worth $237,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in NVO. Strategic Investment Solutions Inc. IL acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $42,000. Albion Financial Group UT raised its position in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares in the last quarter. Finally, Carolina Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $48,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.
Novo Nordisk A/S Trading Down 0.5 %
NVO opened at $80.59 on Thursday. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market capitalization of $361.65 billion, a price-to-earnings ratio of 26.08, a PEG ratio of 0.89 and a beta of 0.45. The company’s 50 day moving average price is $96.63 and its two-hundred day moving average price is $116.04.
Wall Street Analyst Weigh In
View Our Latest Stock Report on Novo Nordisk A/S
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Articles
- Five stocks we like better than Novo Nordisk A/S
- High Flyers: 3 Natural Gas Stocks for March 2022
- Oracle Announces Game-Changing News for the AI Industry
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- How to Calculate Inflation Rate
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.